Aims The main aims of the study were to investigate
the prevalence of pre-diabetes and diabetes mellitus (DM) in patients with
schizophrenia, to compare it with those published in the general population,
and to assess significant associations with dysglycemia defined as having
either pre-DM or DM.
Methods A cross-sectional study carried out in 4
governmental primary psychiatric healthcare centers in Northern West-Bank,
Palestine. Fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) were
measured. The World Health Organization (WHO) criteria for defining pre-DM and
DM were used. Dysglycemia was defined as FBG >110 mg/dl.
Results Based
on WHO criteria, 27 patients (10.8%) had diabetes and 34 (13.6%) had
pre-diabetes. The prevalence of DM in patients with schizophrenia was not
significantly higher than that reported in the general population of Palestine.
However, the prevalence of pre-DM was significantly higher than that reported
in the general population of Palestine. Regression analysis showed that advancing
age and abnormal waist circumference were significant predictors of dysglycemia
in patients with schizophrenia.
Conclusions This study confirmed the
high prevalence of dysglycemia in patients with schizophrenia, supporting the
need for monitoring of blood glucose in this category of patients. The presence
of primary risk factors is more important in the development of dysglycemia in
patients with schizophrenia than exposure to antipsychotic drugs.
The main aims of the study were to investigate the prevalence of pre-diabetes and diabetes mellitus (DM) in patients with schizophrenia, to compare it with those published in the general population, and to assess significant associations with dysglycemia defined as having either pre-DM or DM.
A cross-sectional study carried out in 4 governmental primary psychiatric healthcare centers in Northern West-Bank, Palestine. Fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) were measured. The World Health Organization (WHO) criteria for defining pre-DM and DM were used. Dysglycemia was defined as FBG >110 mg/dl.
Based on WHO criteria, 27 patients (10.8%) had diabetes and 34 (13.6%) had pre-diabetes. The prevalence of DM in patients with schizophrenia was not significantly higher than that reported in the general population of Palestine. However, the prevalence of pre-DM was significantly higher than that reported in the general population of Palestine. Regression analysis showed that advancing age and abnormal waist circumference were significant predictors of dysglycemia in patients with schizophrenia.
This study confirmed the high prevalence of dysglycemia in patients with schizophrenia, supporting the need for monitoring of blood glucose in this category of patients. The presence of primary risk factors is more important in the development of dysglycemia in patients with schizophrenia than exposure to antipsychotic drugs.
Aims The main aims of the study were to investigate the
prevalence of pre-diabetes and diabetes mellitus (DM) in patients with
schizophrenia, to compare it with those published in the general
population, and to assess significant associations with dysglycemia
defined as having either pre-DM or DM.
Methods
A cross-sectional study carried out in 4 governmental primary psychiatric healthcare centers in Northern West-Bank, Palestine. Fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) were measured. The World Health Organization (WHO) criteria for defining pre-DM and DM were used. Dysglycemia was defined as FBG >110mg/dl.
Results
Based
on WHO criteria, 27 patients (10.8%) had diabetes and 34 (13.6%) had
pre-diabetes. The prevalence of DM in patients with schizophrenia was
not significantly higher than that reported in the general population of
Palestine. However, the prevalence of pre-DM was significantly higher
than that reported in the general population of Palestine. Regression
analysis showed that advancing age and abnormal waist circumference were
significant predictors of dysglycemia in patients with schizophrenia.
Conclusions
This
study confirmed the high prevalence of dysglycemia in patients with
schizophrenia, supporting the need for monitoring of blood glucose in
this category of patients. The presence of primary risk factors is more
important in the development of dysglycemia in patients with
schizophrenia than exposure to antipsychotic drugs.
Aims The main aims of the study were
to investigate the prevalence of pre-diabetes and diabetes mellitus (DM) in
patients with schizophrenia, to compare it with those published in the general
population, and to assess significant associations with dysglycemia defined as
having either pre-DM or DM.
Methods A cross-sectional study carried out
in 4 governmental primary psychiatric healthcare centers in Northern West-Bank,
Palestine. Fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) were
measured. The World Health Organization (WHO) criteria for defining pre-DM and
DM were used. Dysglycemia was defined as FBG >110 mg/dl.
Results Based
on WHO criteria, 27 patients (10.8%) had diabetes and 34 (13.6%) had
pre-diabetes. The prevalence of DM in patients with schizophrenia was not
significantly higher than that reported in the general population of Palestine.
However, the prevalence of pre-DM was significantly higher than that reported
in the general population of Palestine. Regression analysis showed that advancing
age and abnormal waist circumference were significant predictors of dysglycemia
in patients with schizophrenia.
Conclusions This study confirmed the
high prevalence of dysglycemia in patients with schizophrenia, supporting the
need for monitoring of blood glucose in this category of patients. The presence
of primary risk factors is more important in the development of dysglycemia in
patients with schizophrenia than exposure to antipsychotic drugs.